CD19 and acute lymphoblastic leukemia: For CRISPRKMT2A::AFF1 blast xenograft assays, CD19+ blasts from the bone marrow of mice that developed CRISPRKMT2A::AFF1 ALL were used for xenotransplantation assays, either after sorting for CD133+ and CD133– fractions, or after PROM1 KO.